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Abstract: A member of Ribonuclease A superfamily, human 
Angiogenin (hAng) is a potent angiogenic factor. Heteronuclear NMR 
spectroscopy combined with induced-fit docking revealed a dual 
binding mode for the most antiangiogenic compound of a series of 
ribofuranosyl pyrimidine nucleosides that strongly inhibit hAng’s 
angiogenic activity in vivo. While modelling suggests the potential of 
a simultaneous binding of the inhibitors at the active and cell binding 
sites, NMR indicates greater affinity for the cell binding site than for 
the active site. Additionally, a 100 nanoseconds molecular dynamics 
simulation have confirmed the stability of the binding at the cell-
binding site with the predicted protein-ligand interactions in excellent 
agreement with the NMR data. This is the first time that a nucleoside 
inhibitor is reported to inhibit completely the angiogenic activity of 
hAng in vivo by exerting dual inhibitory activity on hAng, blocking both 
the entrance of hAng into the cell and the ribonucleolytic activity.  
Introduction 
Human angiogenin (hAng) is a basic protein containing 123 amino 
acids with a molecular weight of about 14.4 kDa [1]. It is the 5th 
member of the pancreatic ribonuclease (RNase) superfamily 
having a 33 % amino acid identity and 56 % overall homology to 
that of RNase A, the prototypic member of this superfamily[2]. 
Angiogenin is an angiogenic factor, playing a major role in the 
growth and establishment of human tumors, whereas RNase A is 
not[3]. In the extracellular environment, secreted hAng binds to a 
170-kDa transmembrane protein that has yet to be fully 
characterized, activating many signal transduction pathways[4]. 
Extracellular hAng also interacts with cell-surface actin promoting 
extracellular matrix degradation allowing thus cell migration and 
invasion[4]. Under growth conditions hAng accumulates in the 
nucleus/nucleolus promoting mRNA transcription and rRNA 
transcription/procession[4-5], while under stress conditions it 
accumulates in the cytoplasm where it forms tiRNAs leading to 
the inhibition of translational initiation[6]. hAng is implicated in 
almost every step of tumorigenesis since it promotes tumour cell 
survival, proliferation, adhesion, migration and invasion, while 
nuclear hAng is necessary for angiogenesis induced by other 
angiogenic factors[7]. In addition to the ribonucleolytic active site 
and the cell-binding site of hAng (residues 60-68 and 108-111), a 
third region has been implicated as necessary for angiogenic 
activity, the nuclear localisation signal (31RRRGL35) [8].  
Importantly, angiogenin presents a ribonucleolytic activity which 
is significantly lower than that of RNase A but essential for its 
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angiogenic activity[9]. Therefore, hAng has been suggested as a 
pharmaceutical target for the development of small molecule 
inhibitors of its enzymatic activity as novel anti-angiogenic 
agents[10]. The active site of hAng contains various binding 
subsites for the phosphate, base, and ribose moieties of the RNA 
substrate (designated Po...Pn, Bo...Bn and Ro...Rn, respectively) 
[8]. 
The central sites are P1, where P-O
5' bond cleavage occurs; B1, 
which binds the 3' pyrimidine; and B2, which interacts with the 
base of the 5' nucleotide (Figure 1). Subsite B1 shows selectivity 
for pyrimidines while B2 prefers purines
[8].  
The three catalytic residues of RNase A, His12, Lys41, and 
His119 of the P1 subsite are conserved in hAng as His13, Lys40 
and His114 [8]. The key B1 residues, Thr45 and Phe120 in RNase 
A, are also maintained in hAng as Thr44 and Leu115. The B2 
subsite is also partially conserved between hAng and RNase A. 
The residues that form the P2 subsite in hAng are His8 and 
Thr11[11], the structural analogues of Lys7 and Arg10 in RNase 
A[12], while Leu115, Asp116, Gln117, and Arg121, in hAng, may 
constitute the subsite P0[11] (Figure 1). 
 
Figure 1. Schematic diagram of the subsites of the hAng active site. The 
residues shown were seen in various crystal and NMR structures to be within 
the sites[8, 11, 13]. 
There are several three-dimensional structures of hAng, including 
crystal structures of the free enzyme[8, 14], crystal structures of 
complexes with small inorganic molecules (phosphate, 
pyrophosphate and sulphate ions)[11, 15], and one solution 
structure by NMR spectroscopy[13]. However, all these structures 
display a closed conformation for the active site, where the key 
pyrimidine-binding subsite, B1, is obstructed by the C-terminal 
segment of hAng. This blockage and the concomitant low 
enzymatic activity of hAng, is achieved primarily by the positioning 
of Gln117 within the B1 pyrimidine binding pocket
[14a]. Due to this 
fact, there is no structural information on hAng-nucleotide 
complexes, in contrast to other members of the RNase A 
superfamily. The relationship between the ribonucleolytic and 
angiogenic activities of hAng implies that potent and selective 
inhibitors of its enzymatic action will be also able to inhibit its 
biological activity. This has been shown so far, for a monoclonal 
antibody[16], an antisense oligodeoxynucleotide [17], peptides 
complementary to the receptor binding site of hAng [18], and a 
small molecule identified by HTS of the NCI and ChemBridge 
libraries [10c, 19]. The structure function relationship of hAng and the 
high degree of conservation between the active sites of hAng and 
RNase A[20], implies that a strategy to develop specific hAng 
inhibitors using as template RNase A inhibitors might be plausible.  
We have tested the validity of this strategy by the evaluation of a 
series of RNase A inhibitors (ribofuranosyl pyrimidine nucleosides 
and their corresponding 1,2,3-triazole derivatives) [21] for their 
antiangiogenic potency in vivo. One of the most potent 
compounds, 4a, and it’s analogue without the triazole ring, 6a, 
have been studied further for their hAng ribonucleolytic inhibitory 
potency in vitro. Furthermore, NMR spectroscopy using binding-
induced resonance perturbations of 15N- and 15N/13C-labeled 
hAng together with molecular modelling studies have been used 
to predict the structural mode of binding of 4a to hAng. In this 
respect, induced-fit docking (IFD) calculations have revealed 
binding interactions of the compound in excellent agreement with 
the NMR data, including novel binding of 4a at the hAng ‘cell 
binding site’ confirmed by molecular dynamics (MD) simulation. 
This provides considerable support for targeting this binding site 
of hAng as a new strategy for developing better anticancer drugs. 
Results and Discussion 
In vivo studies 
The ability of compounds 4a-4e and 6a-6e (Table 1) [21] to inhibit 
angiogenin induced angiogenesis using the chick embryo 
chorioallantoic membrane (CAM) assay [22] has been assessed 
using 2 nM of Pyr1-hAng (the native form of hAng with a 
pyroglutamate residue at the N-terminal) and 6 nM of each ligand 
(Pyr1-hAng: ligand ratio = 1:3). The compounds did not show any 
effects on angiogenesis in the absence of Pyr1-hAng (data not 
shown). Results are presented in Figures 2 and 3. As it is evident 
Pyr1-hAng displays strong angiogenic activity (Figure 2) and its 
presence almost doubles the number of new vessels formed 
(Figure 3) in CAM. This activity is completely inhibited by 4a, 4c, 
4e, and 6a while 4b, 4d, 6b, 6c, 6d, and 6e partially inhibited it 
(Figures 2 and 3). The inhibitors were also tested at a 
concentration of 0.6 nM (Pyr1-hAng: ligand ratio = 10:3), but no 
effect was observed. Therefore, it seems that the inhibitory effect 
is dose dependent. The in vivo inhibitory potency pattern of these 
compounds does not seem to follow their enzymatic inhibitory 
potency in RNase A [21]. However, the most potent compound, 
4a, with a Ki value of 1.6 μM for RNase A (Table 1) completely 
inhibits the biological activity of Pyr1-hAng in the CAM assay.  
The presence of the triazole group seems to influence significantly 
the anti-angiogenic potency. Thus, in general 1,2,3-triazole 5-
substituted uracil furanonucleosides 4a-e are more potent than 
the C-5 substituted uridines 6a-e. However, C-5 substituents H 
and Br, seem to increase the inhibitory potency regardless the 
existence of the triazole linker since ribofuranosyl pyrimidine 
nucleosides 6a and 6c, and their corresponding 1,2,3-triazole 
derivatives, 4a and 4c, bearing respectively the same group at the 
C-5 position inhibit Pyr1-hAng activity at the same extent.  
. 
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Table 1. The chemical structures of the inhibitors studied together with their Ki 
values for RNase A [21] 
 Triazole nucleoside Nucleoside  
 
O
HO
OH OH
N
N
N
NH
N
O
O
X
 
 
C-5-Substituent (-
X) 
Compound  Ki (μM) Compound Ki (μM) 
H 
4a 1.6 ± 0.2 
6a 28.5 ± 
4.5 
Me 
4b 25.8 ± 2.4 
6b 44.1 ± 
6.4 
Br 
4c 
20% 
inhibition 
at 50 μM 
6c 69.1 ± 
2.1 
Cl 
4d 94.8 ± 8.7 
6d 44.5 ± 
4.6 
F 
4e 30.8 ± 4.4 
6e 33.6 ± 
2.6 
 
The influence of the triazole linker is evident when examining the 
effect of the C-5 substituents (H, Me, Br, Cl, and F). The presence 
of F, Cl, or Me seems to weaken the inhibitory potency of the 
nucleosides (Figure 3) whereas the inclusion of the triazole linker 
seems to counteract this effect and 4a, 4c, 4e, 6a and 6e display 
equivalent activities. Thus, the ribofuranosyl pyrimidine 
nucleosides having these C-5 groups display a weaker inhibitory 
potency than their corresponding 1,2,3-triazole derivatives 
(Figures 2 and 3).  
 
Figure 2. Inhibition of the Pyr1-hAng (2nM) angiogenic activity by 6 nM of 
compounds 4a, 4b, 4c, 4d, 4e, 6e, 6d, 6c, 6a, and 6b in the CAM assay. 
We have also analyzed the effect of compounds 4a-e, and 6a-e, 
on the branching of the vessels and the effect is very similar to 
their effect on the total length of the vessels. The diagram on the 
effect on branching of the vessels by compounds 4a-e, and 6a-e, 
is now presented in the supporting information file (Figure S1). 
 
Figure 3. Total length of the vessels measured using the ImagePC image 
analysis software (Scion Corporation, Frederick, MD). 
In vitro studies 
Since compounds 4a and 6a strongly inhibited the angiogenic 
activity of Pyr1-hAng in vivo, the next step was to check whether 
4a and 6a were capable of inhibiting the ribonucleolytic activity of 
Pyr1-hAng in vitro. Using the precipitation assay as described in 
the Experimental Section, for monitoring the inhibition of the 
ribonucleolytic activity of Pyr1-hAng, we observed that the 
concentration of 4a and 6a at which 50 % inhibition of 
ribonucleolytic activity of angiogenin occurs (IC50) is 1 mM and 0.7 
mM, respectively. 4a and 6a are more potent than other common 
Pyr1-hAng pyrimidine mononucleotide inhibitors that have been 
studied, 2'-CMP (Ki=8.7 mM)
[10b], 2'-UMP (Ki=13.1 mM)
[10b] and 3'-
CMP (Ki=13.0 mM)
[10b]. However, the measured IC50 value is 
rather high indicating that the disruption in the enzymatic activity 
might not be the reason for the significant decrease of the 
angiogenic activity of Pyr1-hAng observed in vivo. 
NMR spectroscopy 
The level of the in vitro potency of 4a and 6a does not seem to be 
consistent with the strong in vivo inhibitory potency against Pyr1-
hAng angiogenicity. Therefore, we shifted our interest towards the 
binding of 4a and 6a to hAng. NMR spectroscopy has the ability 
to provide structural information for the identification of binding 
sites even for low-affinity protein-ligand complexes[23]. Having 
gone through the characterization of Met(-1)-hAng through high-
resolution NMR[24], we attempted to exploit the capabilities of 
NMR in the study of transient complexes, and studied the binding 
of 4a and 6a by measuring the 15N,1H-HSQC spectra of 15N-
labeled Met(-1)-hAng in the presence of varying amounts of the 
ligand. For comparison purposes, we have additionally analyzed 
the binding of known hAng inhibitors, 2′-UMP[10b], 3′-CMP[10b], 
NADPH[25], and 5’-ATP[10b] using the same methodology. 
 
1H and 15N resonance perturbations of Met(-1)-hAng residues 
induced by pyrimidine nucleotides 
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Figure 4. Perturbations (in ppm) of the 1H and 15N resonances of the backbone 
amide groups of the residues of 15N-Met(-1)hAng by 3'-CMP (a), 2'-UMP (b), 
NADPH (c), 5'-ATP (d), and 4a (e), measured conditions described in the 
Experimental Section. Dashed lines represent the threshold (two-folds of the 
average value) of the resonance perturbation values while the gaps derive from 
prolines or unassigned residues. 
A five molar excess of 2′-UMP or 3′-CMP induced large shift 
perturbations of the amide protons of Gln12, Lys40, Ile42, Lys50, 
Arg51, Ile56, Ser72, Leu115, Gln117, and Arg121 revealing a 
common binding pattern. Of these residues Gln12, Lys40, Ile42, 
Leu115 and Arg121 are part of the pyrimidine binding region 
(B1R1P1; Figure 1) of the active site of angiogenin, while Gln117 
is the main obstructing residue at the pyrimidine binding subsite 
(B1). The presence of 3′-CMP seems to induce larger 
perturbations of the backbone 1H-15N for these residues (Figure 
4a) than that of 2′-UMP (Figure 4b). An additional resonance 
perturbation has been observed for Thr44 (B1 subsite) with 3′-
CMP that has not been seen with 2′-UMP. Moreover, comparative 
analysis of the acquired HSQC spectra suggests that the 
interaction between Met(-1)-hAng and 2′-UMP or 3′-CMP falls into 
the fast-exchange regime on the NMR time-scale, revealing 
dissociation constant (Kd) value for the two pyrimidine protein 
complexes circa 10-3-10-4 Μ, in agreement with previously 
reported data [10b]. 
1H and 15N resonance perturbations of Met(-1)-hAng residues 
induced by purine nucleotides 
Figures 4c and 4d show resonance perturbations of Met(-1)-
hAng induced by saturating amounts of NADPH (2.5 molar 
excess), and 5′-ATP (3 molar excess), respectively. Both 
molecules induced similar chemical shift changes for residues 
Gln12, Ile42, Arg51, Leu83, Val113, Leu115, and Gln117. Among 
these residues, Gln12, Ile42, and Leu115 are located at the B1P1 
region of the active site, while Gln117 is the residue that impedes 
substrate binding[8]. The purine nucleotides also induced 1H-15N 
resonance perturbations of His8, His13, Tyr14, Lys40, Thr44, 
Phe45, Asn49, Asn68, Val103, Val104, Ala106 and Cys107. His8 
is part of the P2, His13 and Lys40 of the P1, Thr44 of the B1, while 
Asn68 is located in the B2 subsite. Thr7 and Ile46 chemical shifts 
are only influenced by the presence of NADPH. In addition, 
NADPH induced significant resonance shifts of Arg5, Asn43, 
Gly48, Leu69, His114, Ser118 and Ile119 with the resonance 
perturbation of His114 being the greatest (Figure 4c). Asn43 and 
Ser118 are at the B1 subsite while His114 is at P1. Residues which 
exhibit significant difference at their 15N amide resonances in the 
presence of 5′-ATP, compared to those of NADPH, are Lys50, 
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Glu67, and Glu108 of the B2 subsite (Figure 4d). All the above-
mentioned interactions exhibit a fast exchange rate between free 
and bound state on the NMR time-scale, suggesting thus that 
these binding events are characterized by low affinity (Kd>10
-6 M). 
Purine-based inhibitors induce larger resonance perturbations 
of Met(-1)-hAng residues than pyrimidine-based ligands, 
indicating that purines exhibit higher affinity than pyrimidines in 
agreement with previous studies[10a, 10b, 26]. Met(-1)-hAng – 
inhibitor interactions can be assessed by comparing the pattern 
of 1H and 15N resonance perturbations of protein residues induced 
upon binding. In a previous NMR study[27] the binding of 
phosphate anions which occupy the catalytic P1 subsite of 
angiogenin in the crystal[15] induced large perturbations of Gln12, 
Leu115, and Gln117. The largest perturbation induced by the 
binding of 5′-ATP, 2′-UMP, and 3′-CMP to Met(-1)-hAng was that 
for Leu115. Thus, it seems that a phosphate group of these three 
inhibitors occupies the catalytic P1 subsite. This is further 
reinforced by the fact that the binding of 4a which lacks a 
phosphate group did not trigger any perturbation of Leu115 (see 
below). The binding of 5′-ATP induced a small perturbation of 
Ile42 which is in the vicinity of P1 indicating that the γ-phosphate 
group may interact with this residue while the β-phosphate binds 
at P1. This interaction has also been observed by NMR studies of 
the binding of 5′-ADP to angiogenin[27]. No other large perturbation 
of residues has been observed for the binding of 5′-ATP in the 
active site and therefore it seems that the adenosine part of the 
inhibitor protrudes towards the solvent. Both 2′-UMP and 3′-CMP 
induced large perturbation of Arg121 whereas 3′-CMP also 
triggered large perturbations of Ile119 and Phe120. These 
residues constitute a peripheral binding site[11, 27-28] where it 
seems that the pyrimidine bases are bound. 2′-UMP and 3′-CMP 
also induced smaller perturbations of Ile42 and Thr44 (only for 3′-
CMP) which are part of the B1 and we cannot rule out the 
possibility that the pyrimidine bases of these inhibitors bind at this 
subsite as well. 5′-ATP, 2′-UMP and 3′-CMP triggered 
perturbation of Lys50 in a smaller scale, while 2′-UMP and 3′-CMP 
also induced perturbation of Arg51. These residues are outside of 
the active site and were found to interact with sulfate anions in the 
Ang-sulfate complex[11] indicating that these three inhibitors might 
also have an alternative binding site. With the exception of His114, 
the binding of NADPH did not induce any remarkable further 
perturbations beyond those triggered by 5′-ATP. However, 
NADPH induced much more sizeable changes in the residue 
resonances than those measured with all inhibitors tested 
indicating much stronger binding, consistent with results from 
earlier kinetic studies[25].  
1H and 15N resonance perturbations of Met(-1)-hAng residues 
induced by 4a 
The resonance perturbations induced by 4a (6 molar excess, 
the point where no additional spectral changes were observed) 
are presented in Figure 4e. Remarkable differences at the 
resonances of the 1H-15N-HSQC peaks were observed for 
residues Asp41, Ile42, Lys40, Lys50, Arg51, Lys54, Ile56, Glu58, 
Gly62, Glu67, Leu69, Ser72, Tyr94, Gly99, Val103, Ala106, and 
Leu111. During the incremental addition of 4a there were no 
additional residues affected than those observed during the initial 
titration experiment, using the lowest concentration of 4a (ratio 
1:0.125). The NMR data of Met(-1)-hAng in the presence of 4a, 
showed low affinity binding Kd>10
-6 M, as entailed by the fast 
exchange rate between free and bound state on the NMR time-
scale. The resonance perturbations induced by 6a (10 molar 
excess, Figure S2) are much weaker than those induced by 4a 
indicating that the latter binds more tightly. Small differences at 
the resonances of the 1H-15N-HSQC peaks were observed for 
residues Gln12, Phe120 (active site), Gly62, Glu67, Asn68, 
Leu69, (cell-binding site), Asn49, Ile56, Cys57, Ser72, His84, 
Tyr94, and Val103, (Figure S2). No chemical shift perturbations 
of the residues that comprise the nuclear translocation site 
(31RRRGL35) were observed during the titration experiments with 
either 4a or 6a. Chemical shift perturbation were also observed 
for the segment Ser37-Ile42, with residues Ser37-Lys40 being 
those that exhibit the largest values (close or above the threshold, 
(Figure 4)). However, even though this segment is not far from the 
NLS (31-35), no perturbations have been observed for the NLS 
site. 
Comparison of the 1H-15N-HSQC spectra of 4a with those of 
2′-UMP, 3′-CMP, NADPH, and 5′-ATP reveals that the 
perturbations of Asp41, Gly99 and Leu111 were only induced by 
the presence of 4a while perturbations of Ile42, Lys50, Arg51 and 
Lys54 were caused by the presence of all five ligands (4a, 2′-UMP, 
3′-CMP, NADPH, 5′-ATP). Perturbations of residues Lys40, Ile56, 
Gly62, Leu69, Ser72, Tyr94, Val103 and Ala106 were also 
induced by the presence of 2′-UMP. With the exception of Tyr94 
and Ala106 the same residues were also influenced by 3′-CMP. 
Changes to 15N-HSQC peaks of Lys40, Leu69 and Ala106 were 
also observed in the presence of NADPH while the 1H-15N-HSQC 
peaks of Lys40, Glu58, Gly62, Glu67, Ser72, Tyr94 and Val103 
were also shifted by the presence of 5′-ATP. 
With the exception of Lys40 and Ile42, 4a did not induce any 
other resonance perturbations of the same active site residues of 
Met(-1)-hAng as 5′-ATP, NADPH, 2′-UMP and 3′-CMP. Therefore, 
it seems that 4a does not bind only at the active site of the enzyme. 
The perturbations of Lys40 and Ile42 (Figure 5) are the smallest 
among those induced by 4a, further supporting the existence of 
another binding site for this inhibitor. The most structurally 
significant perturbations are those of Glu58, Gly62, Glu67 and 
Leu69 (Figure 5). These residues are part of the cell binding site 
of angiogenin[8] suggesting that this is the other binding site of 4a. 
The small perturbations of Lys40 and Ile42 imply that 4a also 
binds at the active site in agreement with the expression of 
inhibition of the ribonucleolytic activity by 4a.
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Figure 5: Titration of Met(-1)-hAng with 4a monitored by NMR spectroscopy. Superimposition of the 15N, 1H HSQC acquired spectra in absence (black) and in 
presence of successive additions of compound 4a (color represents each molar ratio, 1:0.125 - light blue, 1:0.25 – yellow, 1:0.5 – green, 1:1 – purple, 1:6 – red). 
Specific regions are magnified and correspond to polypeptide’s amino acids implicated in the 4a binding. 
Figure 6. The binding modes of 4a to hAng derived from NMR and modeling studies. (a) The structural model of the hAng-4a complex derived from the fourth 
ranked pose of IFD 1 calculations (Table 2) targeting the active site; (b) the structural model of the hAng-4a complex derived from the top-ranked pose of IFD-2b 
calculations targeting the cell binding site; (c) stereo views of the interactions of 4a with hAng at the cell binding site; (d) stereo views of the interactions of 4a with 
hAng at the active site; hAng residues are drawn as ball-and-stick models, while hydrogen bonds are indicated by dashed lines. Hydrogen bonds were assigned 
using Maestro[29] default settings throughout: maximum distances 2.8 Å, donor and acceptor minimum angles of 120° and 90°, respectively.  
 
Modelling of the binding modes of 4a in complex with Pyr1-hAng 
Computational induced-fit docking analysis[29-30] was used to 
derive three dimensional structures for Pyr1-hAng in complex with 
4a. These calculations were performed as described in the 
Experimental Section targeting interactions at the active and cell 
binding sites. The results of the IFD calculations in terms of 
GlideScore, Prime Energy and IFDscore are shown in Table 2. 
The fourth ranked pose from IFD 1 calculations that targeted 
interactions at the active site matches the experimental NMR 
perturbations. In this binding location of hAng (Figure 6a), 4a 
forms hydrogen bond interactions with the main chain atoms of 
Ile42 and with the side chain atoms of Lys40, and Asp41 (Figure 
6b) in agreement with the NMR observations.  
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Using a similar standard IFD protocol for the cell binding site failed 
to find a docking solution compatible with the NMR data. 
Accordingly, more extensive conformational sampling of this 
binding site was explored, as described for the IFD-2a and IFD-
2b calculations in the Experimental Section. The top-ranked pose 
from IFD-2b exhibited binding features in excellent agreement 
with NMR data. In this binding hAng location (Figure 6c), the 
ligand forms hydrogen bond interactions with Lys54, Ile56, Glu58, 
Gly62, and Glu67 (Figure 6d) in the cell binding site. Each of these 
residues, according to the NMR data, seem to be implicated in 
protein-inhibitor interaction, since residues’ 1H-15N resonances 
are affected during the titration as described in detail above. 
 
Table 2. Results of the induced fit docking calculations[a] 
Binding Site IFD 
Protocol 
Pose 
Rank 
GlideScore  Prime 
Energy 
IFDscore  
Active Site IFD 1 1 
4* 
    -5.92 
    -4.72 
-5157.5 
-5146.9 
-263.8 
-262.1 
Cell Binding 
Site 
IFD 2a 1     -6.42 -5161.5 -264.5 
  17     -4.34 -5148.7 -261.8 
 
IFD 2b  1*     -6.62 -5157.2 -264.5 
[a] Calculations as described in Experimental Section. The NMR consistent 
predicted protein ligand complexes are highlighted with an asterisk * in italics. 
Units are kcal/mol. 
Using a similar standard IFD protocol for the cell binding site failed 
to find a docking solution compatible with the NMR data. 
Accordingly, more extensive conformational sampling of this 
binding site was explored, as described for the IFD-2a and IFD-
2b calculations in the Experimental Section. The top-ranked pose 
from IFD-2b exhibited binding features in excellent agreement 
with NMR data. In this binding hAng location (Figure 6c), the 
ligand forms hydrogen bond interactions with Lys54, Ile56, Glu58, 
Gly62, and Glu67 (Figure 6d) in the cell binding site. Each of these 
residues, according to the NMR data, seem to be implicated in 
protein-inhibitor interaction, since residues’ 1H-15N resonances 
are affected during the titration as described in detail above.  
The flexibility of the residues in the cell-binding site meant that 
there were significant conformational changes in the cell binding 
site from the crystal structure of Pyr1-hAng used as input. 
Considering that we refined complexes with a common base-line 
energy (same protein starting conformation), it is predicted by 
Prime Energy that these conformational changes for the 
experimentally consistent cell binding site protein-ligand pose (-
5157.2 kcal/mol) result in a more favorable complex energy 
compared to its active site equivalent (-5146.9 kcal/mol). In a 
similar manner, and consistent with the proposal of the cell 
binding site being the other binding site of the inhibitor, the 
IFDscores for the experimentally consistent poses are -264.5 and 
-262.1 kcal/mol for the cell-binding and active sites, respectively, 
with a difference of 2 kcal/mol considered significant (Schrödinger, 
personal communication). Towards further validating the novel 
binding of 4a at the cell-binding site, a 100 ns MD simulation was 
performed. Small and stable RMSD fluctuations of the Cα 
(average RMSD = 0.258 Å) and protein sidechains (average 
RMSD = 0.489 Å) over the simulation production run were 
observed as displayed in Figure 7. Figure 8 shows the protein-
ligand hydrogen bond contacts as a fraction of their occurrence 
throughout the simulation; the major contacts with residues 
(Lys54, Glu67, Gly62, Glu58, Ile56) are in excellent agreement 
with experiment, ranging from hydrogen bonding with Lys54 
94.3% of the time to 34.7% for Ile56. Additionally, clustering of 
binding site conformations resulted in one dominant cluster (99% 
of frames) consistent with the stability of 4a binding at the site. 
Figure 7. RMSD of protein Cα and sidechain atoms with respect to time from 
a 100 ns molecular dynamics simulation of 4a bound at the Pyr1-hAng cell-
binding site. The uniform and small fluctuations around equilibrium values 
reflect the stability of the system over the course of the simulation. 
 
Figure 8. Hydrogen bond contacts of 4a with amino acid residues at the Pyr1-
hAng cell-binding site from a 100 ns molecular dynamics simulation. Contacts 
are expressed as a fraction of their occurrence during the simulation. 
Finally, to probe whether the binding of 4a at the two binding sites 
occurs sequentially or simultaneously, additional IFD calculations 
of a 4a ligand to the active site was performed using 
representative complexes from the MD simulation, retaining 4a 
bound at the cell-binding site. These docking calculations 
revealed a similar experimentally consistent binding pose of 4a 
(hydrogen bond interactions with Cys39, Lys40, Asp41, Ile42) to 
that obtained in the original IFD 1 calculations (ligand heavy atom 
RMSD of 1.879 Å). Interactions with protein residues are in 
excellent agreement with the NMR data since the NMR titration 
experiments revealed that chemical shift perturbations of the 
residues of both regions (active site and cell binding site) are 
observed simultaneously even at the lowest ligand concentration 
(ratio protein:ligand = 1:0.125). This suggests the potential for 
binding to occur simultaneously; however, crystallographic 
evidence would fully confirm this to be the case. There have been 
numerous reports of the successful application of IFD to predict 
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significant ligand dependent conformational changes in 
agreement with experiment together with their effects on 
biochemical pathways and mechanisms[31]. Likewise, here we 
have been able to report an additional success, highlighting the 
potential of the concerted use of IFD with careful parameter 
selection/application in combination with experimental NMR data, 
to elucidate new and previously unidentified binding sites on 
protein/enzyme surfaces. MD simulation, as was applied here, 
can be used to further validate newly predicted geometries. 
Conclusions 
In summary, we have provided evidence for the strong 
antiangiogenic potency in vivo of a series of ten RNase A 
inhibitors (ribofuranosyl pyrimidine nucleosides and their 
corresponding 1,2,3-triazole derivatives). The 1,2,3-triazole 5-
substituted uracil furanonucleosides were more potent than the 
C-5 substituted uridines. However, the strong antiangiogenic 
potency of these compounds was not consistent with their 
enzymatic inhibition in vitro. NMR data together with induced-fit 
docking calculations and MD simulation revealed a novel binding 
mode for 4a at hAng.  
Moreover, since NMR titration experiments revealed that 
chemical shift perturbations of the residues of both regions (active 
site and cell binding site) are observed simultaneously even at the 
lowest ligand concentration, and docking calculations are in 
agreement with a binding to occur simultaneously. The larger 
chemical shift changes observed for the residues of the cell 
binding site with respect to those of the active site, could possibly 
be indicative for stronger binding, which may be related with 
higher specificity 
The difference in binding data between NMR and biochemical 
assays may be attributed to the fact that the NMR study was 
performed in a CH3COONa (50 mM) buffer with pH 5.0, while the 
biochemical in vitro and in vivo assays were performed in a MES 
buffer (100 mM) supplement with 100 mM NaCl at pH 6.0 and in-
cell, respectively, where completely different experimental 
conditions were applied. Therefore, the protonation states of 
many amino acids side chains, which are expected to be 
implicated in the protein – ligand interaction, are different in these 
three different solutions. It is well-established in NMR, that known 
binding events, characterized as strong with Kd <10
-9 M are 
studied by NMR and Kds found in ~10
-3 to 10-6 M. 
This is the first time that a nucleoside is reported to exert dual 
inhibitory action on hAng, blocking both the entrance of hAng into 
the cell and also its ribonucleolytic activity. The output of this work 
will therefore facilitate the rational design and development of new 
anti-angiogenic compounds targeting the angiogenin cell binding 
site. 
hAng seems to play key roles in a plethora of biological processes 
and is also implicated in almost every step of tumorigenesis. It has 
thus become a validated diagnostic tool, prognosis and therapy-
monitoring marker in cancer [4, 32] for physicians[33], as well as a 
validated pharmaceutical target for the development of new anti-
cancer agents[34].  
The direct relationship between the ribonucleolytic and 
angiogenic activities of hAng implied that potent and selective 
inhibitors of its enzymatic action could be also able to inhibit its 
biological activity2. However, blocking only the enzymatic active 
site may not be efficient because it could not probably prevent the 
protein interactions that hAng forms with different protein partners 
which is an important regulatory mechanism for the diverse 
cellular functions of hAng that promote cancer establishment and 
progression. We have recently performed a proteomic analysis of 
hAng interactions by mass spectrometry (MS)[35] and identified, 
among others, proliferating cell nuclear antigen (PCNA) as a 
novel hAng protein partner. PCNA, which forms a ring around the 
DNA regulating DNA replication, plays a central role in 
determining both tumour progression and the outcome of 
anticancer treatment[36]. 
Inhibitors like 4a that present dual action and can block both the 
enzymatic activity and mainly the cell binding site, will have the 
advantage of blocking the biological action of hAng, regardless of 
the cause, since they will prevent any interaction with its target 
cells. Furthermore, such inhibitors, will circumvent the caveat of 
neutralizing all circulating hAng in the plasma where its 
concentration is significantly high ( ~250 ng/ mL)[34], and the 
amount of inhibitors needed to directly target hAng may be 
unreachable. Finally, since normal cells do not require hAng to 
survive and grow and hAng’s internalization and subsequent 
nuclear translocation occur only in cancer cells and in proliferating 
endothelial cells, blocking the cell binding site of hAng will 
selectively inhibit the growth and proliferation of cancer cells and 
proliferating endothelial cells but spare normal cells, presenting 
thus less side-effects and lower toxicity[34]. 
Experimental Section 
Overexpression and purification of 15N- and 15N/13C-labeled and 
unlabeled Met(-1)-hAng: The construction of the recombinant vector 
containing the gene of hAng and the purification procedure of the protein, 
were described elsewhere[11]. Labeled Met(-1)-hAng with 15N- and 15N/13C 
was prepared as previously described[24].  
Angiogenic activity:Met(-1)-hAng was converted to the authentic Pyr1 
human form (Pyr1-hAng) which contains a pyroglutamic acid residue at 
position 1 as described previously[37]. The inhibitory potency of 4a-4e and 
6a-6e[21], on Pyr1-hAng induced angiogenesis, was assessed by using the 
CAM assay[38].  Briefly, Leghorn fertilised eggs were incubated for 4 days 
at 37 °C, when a window was opened on the egg shell, exposing the CAM. 
The window was covered with tape and the eggs were returned to the 
incubator until day 9, when the test molecules were applied. Pyr1-hAng 
alone or in combination with the inhibitors were added as a solution in a 
final volume of 60 µL, at day 9 of chicken embryo development, on an area 
of 1 cm2 of the CAM, restricted by a plastic ring. In a different group of 
eggs, which was used as control, only PBS was applied. The inhibitors 
alone were also tested for antiangiogenic activity in the CAM assay. After 
48 h of incubation at 37 °C, images were taken through a stereoscope 
equipped with a digital camera and the total length of the vessels was 
measured using the ImagePC image analysis software (Scion Corporation, 
Frederick, MD). Assays for each test sample were carried out three times 
and each experiment contained 6 eggs per data point. 
Precipitation assay with human angiogenin: Inhibition of the 
ribonucleolytic activity of Pyr1-hAng was quantified following the Bond 
method[39] as used in other studies[40]. Pyr1-hAng solution was determined 
spectrophotometrically using absorption coefficient 280nm=12500 M-1cm-1 
[41]. The reaction buffer was 0.1 M MES, 0.1 M NaCl, pH 6.0, and the final 
volume of the reaction was 300 μL. The final concentrations of Pyr1-hAng, 
tRNA, and BSA in the reaction were 1 μM, 10 μM, and 3 μM, respectively. 
The inhibitors, 4a or 6a, were pre-incubated with Pyr1-hAng at 37 oC for 
30 minutes. The reaction was stopped six hours later, by the addition of 
300 μL of fresh ice-cold solution of 40 mM lanthanum nitrate, 6 % (v/v) 
perchloric acid.  Stopped reactions were maintained on ice for 15 min, and 
insoluble tRNA was removed by centrifugation at 4 oC for 15 min at 
maximum speed on a bench centrifuge. The amount of cleaved tRNA was 
determined from the absorbance of the supernatant fraction at wavelength 
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of 260 nm (A260). A blank run (without enzyme) was also conducted and 
the A260 value measured from this blank was subtracted from the 
corresponding reaction samples to eliminate any endogenous tRNA 
hydrolysis. 
NMR experiments:To investigate the binding of Met(-1)-hAng with 4a and 
6a and to compare it to that of other pyrimidine (2′-UMP and 3′-CMP) and 
purine (NADPH, 5′ATP) nucleosides, we performed titration experiments 
followed by the acquisition of 2D 1H-15N HSQC NMR spectra. Analysis of 
the resonances, which are influenced during the titration experiments 
allows the identification of residues that are affected by the binding of 
ligands to Met(-1)-hAng. We conducted five different NMR titration 
experiments of 15N labeled protein (0.4 – 0.6 mM), one for each ligand. 
Measurements were performed in a buffer consisting of 50 mM sodium 
acetate, 0.2 mM EDTA, pH 5.0, as described in our previous study for the 
sequence-specific assignment of Met(-1)-hAng 1H, 15N and 13C 
resonances[24]. This buffer does not affect the enzymatic activity of 
angiogenin, as reported in previous NMR studies[27]. 1H–15N HSQC spectra 
were recorded after each addition of the nucleosides at 298 K on a Bruker 
Avance III High-Definition, four-channel 700 MHz NMR spectrometer 
equipped with a cryogenically cooled 5 mm 1H/13C/15N/D Z-gradient probe. 
The incremental addition of each putative ligand was completed at the 
point (concentration) that no spectral changes were observed. Combined 
chemical shift perturbations were calculated using the equation: Δav = 
[(ΔδHN)2+(ΔδN/5)2]1/2 [23].  
Induced-fit Docking analysis of Pyr1-hAng - 4a complex: The 4a ligand 
was prepared for calculations using LigPrep 3.6[29] with the OPLS3 
forcefield[42], while  hAng was prepared using the native Pyr1-hAng crystal 
structure (PDB id: 5EOP[11]). The initial setup of the Pyr1-hAng structure 
was performed using Schrodinger’s “Protein Preparation Wizard” [29]. 
Water molecules were deleted, bond orders assigned, and hydrogen 
atoms added, with protonation states for basic and acidic residues based 
on residue PROPKA pKa values at normal pH (7.0). Subsequent 
optimization of hydroxyl groups, histidine protonation states and C/N atom 
“flips”, and side-chain O/N atom flips of Asn and Gln was based on 
optimizing hydrogen bonding patterns. Finally, an “Impref” minimization 
using the OPLS3 force field[42] was performed to remove steric clashes and 
bad contacts but with heavy atoms constrained to within 0.3 Å (RMSD) of 
their crystallographic positions. Schrödinger IFD calculations[30] of 4a to 
hAng were performed to predict protein-ligand binding interactions 
consistent with the observed NMR residue perturbations. Accordingly, two 
hAng binding regions were targeted. The first IFD calculation (IFD 1 – 
Active Site) aimed at predicting the binding close to the active site; the 
centroid of residues Lys40, Asp41, Ile42 and Tyr94 which exhibited NMR 
perturbations in this region were used to define the box centre. The IFD 
itself consisted of three calculation Stages (I-III). In Stage I, docking was 
performed using Glide 7.1 standard-precision (SP) docking with default 
parameters and with a maximum of 20 ligand binding poses saved. In 
Stage II, residues within 5 Å of the initial protein-ligand poses were refined 
using Prime 4.4. Finally, in Stage III up to 20 protein structures within 30 
kcal/mol of the lowest-energy complex structure were used for Glide-SP 
ligand re-docking calculations. The second IFD calculation (IFD 2a – Cell 
Binding Site) aimed at predicting the binding close to the cell binding site 
and required a more extensive approach to sampling the receptor-ligand 
conformational space to identify the binding interactions consistent with 
the NMR data. The centroid of residues Glu58 and Glu67 at opposite ends 
of the cell binding site were used to define the box centre. IFD parameters 
were applied as for the active site region except for the following: in Stage 
I residues 59-70 were mutated to Ala for the initial Glide-SP docking; in 
Stage II residues were rebuild and refined using Prime within 7 Å of these 
initial protein-ligand poses for the final (Stage III) redocking calculations. 
One receptor-ligand pose from this protocol gave a pose partly consistent 
with the experimental NMR data which involved hydrogen bond contacts 
from ligand to Glu67 O and the pyrimidine CO with the Lys54 sidechain 
NH3+. Using this pose (centroid of 4a in binding site used to define the grid 
box centre) and these hydrogen bonds as constraints for a second IFD 
calculation (IFD 2b – Cell Binding Site), the IFD was repeated without 
mutations and the same setting as for the IFD 1 calculation. The resulting 
receptor-ligand poses from the IFD calculations were analysed in terms of 
structure and agreement with experiment (NMR chemical shift 
perturbation), ligand re-docking GlideScore (GS), and IFDscore (ligand re-
docking GS + 5% Prime energy from the refinement calculation). 
Molecular Dynamics Simulation of Pyr1-hAng - 4a cell-binding 
complex: The experimentally consistent IFD 2b predicted binding pose of 
4a at the cell-binding site was used as input for MD using Desmond version 
4.6. The initial set-up involved soaking the system with a pre-equilibrated 
TIP3P model orthorhombic water box (sides a = 66.66 Å, b = 55.16 Å, c = 
50.30 Å, volume 184,951 Å3) allowing for a 10 Å buffer region between 
protein and box sides, and neutralizing the system with Cl- ions. This setup 
procedure produced 5130 water molecules with the final system consisting 
of 17,368 atoms.  Forcefield parameters for the protein-ligand systems 
were assigned using the OPLS3 forcefield[42]. Heavy atom bond lengths 
with hydrogens and the internal geometry of water molecules were 
constrained using the SHAKE algorithm. Periodic boundary conditions 
(PBC) were applied and a cut-off of 9.0 Å for non-bond interactions, with 
electrostatic interactions treated using the Particle Mesh Ewald (PME) 
method[43]. Prior to the MD production run, a relaxation protocol was 
employed as follows: (a) 2000 steps minimization with the solute restrained 
and a loose convergence criteria of 50 kcal mol-1  Å-1; (b) 2000 steps 
minimization (no restraints) with a convergence criteria of 1 kcal mol-1 Å-1; 
(c) a short Brownian dynamics 50-ps simulation using a temperature (T) of 
10 K with solute heavy atoms restrained; (d) a 50-ps simulation in the NVT 
ensemble using T = 10 K (thermostat relaxation constant = 0.1 ps) with 
solute heavy atoms restrained (e) a 100-ps simulation in the NPT 
ensemble using T = 10 K (thermostat relaxation constant = 0.1 ps) and 
pressure (P) = 1 atm (barostat relaxation constant = 50 ps) with solute 
heavy atoms restrained; (e) solvate pocket as necessary (f) a 100-ps 
simulation in the NPT ensemble (T = 300 K; thermostat relaxation constant 
0.1 ps; P = 1 atm; barostat relaxation constant 50.0 ps) with solute heavy 
atoms restrained; and (g) a 200-ps simulation in the NPT ensemble (T = 
300 K; thermostat relaxation constant 0.1 ps; P = 1 atm; barostat relaxation 
constant 2.0 ps) with no restraints. For all the above, the relaxation 
constants relate to Berendsen thermostats and barostats. Following the 
relaxation, a 100 ns production run in the NPT ensemble (T = 300 K, 
thermostat relaxation time = 1.0 ps; P = 1 atm; barostat relaxation time = 
2.0 ps) was performed using a Nose-Hoover thermostat and Martyna-
Tobias-Klein barostat[44]. A multiple time step RESPA integration algorithm 
was used with time steps of 2, 2, and 6 fs for bonded, ‘‘near’’ non bonded, 
and ‘‘far’’ non bonded interactions, respectively. Energy and trajectory 
atomic coordinate data were collected every 1.2 and 5.0 ps, respectively. 
Visualization and analysis of the MD trajectory was performed employing 
Desmond Maestro’s simulation analysis tools. Exploiting Maestro’s 
Desmond trajectory clustering tool and the hierarchical cluster linkage 
method, clustering of 1000 trajectory frames considering the binding site 
conformations (ligand and protein residues within 7 Å) into 10 clusters 
based on atomic RMSDs was performed[45]. Using the MD representative 
complexes from the two largest clusters (water and Cl- ions deleted) and 
with 4a retained bound at the cell binding site, IFD was repeated for a 4a 
molecule binding to the active site using the same settings as outlined 
above for IFD 1 – Active Site; this allowed us to consider whether the 
binding of 4a to the active and cell-binding sites can occur simultaneously.  
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A nucleoside is reported to disrupt the biological function of human angiogenin in vivo and its enzymatic activity in vitro. NMR 
spectroscopy revealed simultaneous binding at the cellular and active site of angiogenin while computational modeling in line with 
NMR data suggested the protein-ligand interactions.  
 
 
